126 related articles for article (PubMed ID: 21316219)
1. Optimisation of ITK inhibitors through successive iterative design cycles.
Herdemann M; Weber A; Jonveaux J; Schwoebel F; Stoeck M; Heit I
Bioorg Med Chem Lett; 2011 Mar; 21(6):1852-6. PubMed ID: 21316219
[TBL] [Abstract][Full Text] [Related]
2. Identification of potent ITK inhibitors through focused compound library design including structural information.
Herdemann M; Heit I; Bosch FU; Quintini G; Scheipers C; Weber A
Bioorg Med Chem Lett; 2010 Dec; 20(23):6998-7003. PubMed ID: 20965724
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
4. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
[TBL] [Abstract][Full Text] [Related]
5. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
[TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
8. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Velankar AD; Quintini G; Prabhu A; Weber A; Hunaeus G; Voland B; Wuest M; Orjeda C; Harel D; Varghese S; Gore V; Patil M; Gayke D; Herdemann M; Heit I; Zaliani A
Bioorg Med Chem; 2010 Jun; 18(12):4547-59. PubMed ID: 20472447
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
12. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
14. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
15. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
[TBL] [Abstract][Full Text] [Related]
16. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
17. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
[TBL] [Abstract][Full Text] [Related]
18. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
[TBL] [Abstract][Full Text] [Related]
19. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
